New and emerging therapies for acute myeloid leukaemia

19Citations
Citations of this article
90Readers
Mendeley users who have this article in their library.

Abstract

The treatment of acute myeloid leukemia (AML) has remained relatively unchanged for the past 3-4 decades with generally poor outcomes, especially in elderly populations unfit for intensive therapy. Recent advancements, however, have identified several cytogenetic and molecular markers that have not only improved prognostication but have also led to the development of several new targeted therapies for specific subpopulations. In 2017, the US Food and Drug Administration approved four new treatments with indications for fms like tyrosine kinase 3 (FLT3)-mutated AML (midostaurin), newly diagnosed or relapsed/refractory CD33+AML (gemtuzumab ozogamicin), newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (CPX-351) and relapsed/refractory AML with an isocitrate dehydrogenase (IDH)2 mutation (enasidenib). These newly approved therapies have demonstrated improved response in their target populations in several pivotal clinical trials with some also demonstrating improved overall survival. Additional novel therapies in development for AML include agents that target B cell lymphoma 2, FLT3, IDH1, the ubiquitination pathway, as well as cell therapy using engineered T cells with chimeric antigen receptors. This review provides a summary of the four newly approved therapies for AML, as well as several promising therapies currently in development.

References Powered by Scopus

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

7648Citations
N/AReaders
Get full text

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

4477Citations
N/AReaders
Get full text

Genomic classification and prognosis in acute myeloid leukemia

3160Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

618Citations
N/AReaders
Get full text

Progress in cancer mortality, incidence, and survival: A global overview

177Citations
N/AReaders
Get full text

Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

137Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Davis, J. R., Benjamin, D. J., & Jonas, B. A. (2018, December 1). New and emerging therapies for acute myeloid leukaemia. Journal of Investigative Medicine. BMJ Publishing Group. https://doi.org/10.1136/jim-2018-000807

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

55%

Researcher 9

29%

Professor / Associate Prof. 4

13%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 14

37%

Medicine and Dentistry 11

29%

Agricultural and Biological Sciences 7

18%

Immunology and Microbiology 6

16%

Save time finding and organizing research with Mendeley

Sign up for free